Cargando…

Cerebral Blood Flow and Glucose Metabolism in Appetite-Related Brain Regions in Type 1 Diabetic Patients After Treatment With Insulin Detemir and NPH Insulin: A randomized controlled crossover trial

OBJECTIVE: To test the hypothesis that insulin detemir, which is associated with less weight gain than other basal insulin formulations, exerts its weight-modulating effects by acting on brain regions involved in appetite regulation, as represented by altered cerebral blood flow (CBF) or cerebral gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Golen, Larissa W., IJzerman, Richard G., Huisman, Marc C., Hensbergen, Jolanda F., Hoogma, Roel P., Drent, Madeleine L., Lammertsma, Adriaan A., Diamant, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836102/ https://www.ncbi.nlm.nih.gov/pubmed/24130356 http://dx.doi.org/10.2337/dc13-0093

Ejemplares similares

Effects of Insulin Detemir and NPH Insulin on Body Weight and Appetite-Regulating Brain Regions in Human Type 1 Diabetes: A Randomized Controlled Trial
por: van Golen, Larissa W., et al.
Publicado: (2014)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin
por: Begg, Denovan P., et al.
Publicado: (2015)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Cerebral Blood Flow and Glucose Metabolism Measured With Positron Emission Tomography Are Decreased in Human Type 1 Diabetes
por: van Golen, Larissa W., et al.
Publicado: (2013)

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)
por: Wheeler, Mark D., et al.
Publicado: (2018)

Cerebral blood flow and glucose metabolism in healthy volunteers measured using a high-resolution PET scanner
por: Huisman, Marc C, et al.
Publicado: (2012)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
por: Mathiesen, Elisabeth R., et al.
Publicado: (2012)

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes: A Randomized Clinical Trial
por: Razzaghy-Azar, Maryam, et al.
Publicado: (2021)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
por: Lucidi, Paola, et al.
Publicado: (2011)

Study of a New Modified Insulin (Type N.P.H.)
por: Mukherjee, Surath Kumar
Publicado: (1952)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review
por: Hagenmeyer, Ernst-Günther, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2m8v20l2nao9lnbbvh24sdoo7d